Filter Results:
(925)
Show Results For
- All HBS Web
(1,282)
- People (5)
- News (172)
- Research (925)
- Events (6)
- Multimedia (12)
- Faculty Publications (759)
Show Results For
- All HBS Web
(1,282)
- People (5)
- News (172)
- Research (925)
- Events (6)
- Multimedia (12)
- Faculty Publications (759)
Sort by
- 10 Jun 2008
- First Look
First Look: June 10, 2008
Formula’ Harvard Business School Case 808-127 Robert Wessman took over Actavis in 1999 when it was a failing 90-person domestic generic pharmaceutical maker in Iceland. Within 7 years he had brought Actavis to number 5 worldwide, with... View Details
Keywords: Martha Lagace
- 05 Jul 2004
- Research & Ideas
Radical Change, Entrepreneurial Opportunity
tightly coupled relationships with customers to engage in trials of different product concepts, producers and users can jointly learn about and make sense of the new technology. For instance, Surface Logix, a firm with highly sophisticated, flexible technology called... View Details
- July 1981 (Revised December 1984)
- Case
American Distilling Co. (A)
Fruhan, William E., Jr. "American Distilling Co. (A)." Harvard Business School Case 281-008, July 1981. (Revised December 1984.)
- June 2010 (Revised February 2013)
- Background Note
The Precautionary Principle
By: Michael W. Toffel and Nazli Z. Uludere Aragon
This note describes the precautionary principle and its key tenets, highlights challenges associated with its use, and includes many examples of its application, primarily within the realm of regulating activities based on the risk of harm to human health and the... View Details
Keywords: Governing Rules, Regulations, and Reforms; Policy; Health Disorders; Business and Government Relations; Safety; Natural Environment; Pollutants; Agriculture and Agribusiness Industry; Chemical Industry; Pharmaceutical Industry
Toffel, Michael W., and Nazli Z. Uludere Aragon. "The Precautionary Principle." Harvard Business School Background Note 610-043, June 2010. (Revised February 2013.)
- 26 Apr 2011
- Op-Ed
HBS Faculty Comment on Environmental Issues for Earth Day
what we have learned about how best to accelerate innovation from industries like IT and pharmaceuticals - sectors in which the US leads the world and which saw enormous rates of technical progress over the last fifty years. The results... View Details
- 2018
- Working Paper
Information Provision and Innovation: Natural Experiment of Herbal Patent Prior Art Adoption at the United States and European Patent Offices
By: Prithwiraj Choudhury and Tarun Khanna
We exploit a natural experiment to study how codifying information about prior innovation affects subsequent innovation. A codified database of traditional Indian herbal formulations was adopted by the European Patent Office (EPO) and the U.S. Patent and Trademark... View Details
Keywords: Patents; Plant-Based Agribusiness; Ethnicity; Health Care and Treatment; Pharmaceutical Industry; Pharmaceutical Industry; China; India
Choudhury, Prithwiraj, and Tarun Khanna. "Information Provision and Innovation: Natural Experiment of Herbal Patent Prior Art Adoption at the United States and European Patent Offices." Harvard Business School Working Paper, No. 14-079, February 2014. (Revised January 2018.)
- December 2010 (Revised April 2012)
- Background Note
Stalemate at the WTO: TRIPS, Agricultural Subsidies, and the Doha Round
By: Arthur A. Daemmrich
This note analyzes disputes over intellectual property enforcement and agricultural trade barriers at the center of the Doha Round of World Trade Organization (WTO) negotiations. Fundamental principles of intellectual property rights and agricultural subsidies are... View Details
Keywords: Agribusiness; Trade; Globalization; Governance; International Relations; Intellectual Property; Agreements and Arrangements; Pharmaceutical Industry; Pharmaceutical Industry
Daemmrich, Arthur A. "Stalemate at the WTO: TRIPS, Agricultural Subsidies, and the Doha Round." Harvard Business School Background Note 711-043, December 2010. (Revised April 2012.)
- 12 Apr 2010
- Research & Ideas
One Report: Better Strategy through Integrated Reporting
electronics company Philips; the Danish pharmaceutical company Novo Nordisk; the Brazilian cosmetics company Natura; and the U.S.-based technology and aerospace company United Technologies all come to mind. All have done a very good job... View Details
Keywords: by Martha Lagace
- 10 Jan 2005
- Research & Ideas
Motivation and the Cross-Sector Alliance
medicines. Furthermore, Chile offers no reimbursements for pharmaceutical expenses, so this tends to add to customers' negative disposition." To respond to this situation, FASA considered a possible collaboration with the Fundación... View Details
- 12 Nov 2013
- First Look
First Look: November 12
GlaxoSmithKline: Sourcing Complex Professional Services Pharmaceutical company GlaxoSmithKline (GSK) uses an innovative new approach to procuring outside legal counsel: it replaces relationship-based selection and law firms' traditional... View Details
Keywords: Sean Silverthorne
- 25 Oct 2004
- Research & Ideas
Planning for Surprises
just two suppliers, while Great Britain has five suppliers to reduce the risk of supply disruptions. While fear of lawsuits has played a role, the fundamental problem is that the economics of vaccine production are unattractive for View Details
Keywords: by Martha Lagace
- 09 Feb 2004
- Research & Ideas
Got a New Strategy? Now Make it Happen
It does so by fitting the organization to the strategy and increasing fitness, the capacity of the organization to learn and change. Since then, this process has been used in more than 150 businesses in the retail, hospitality, high technology, banking, and View Details
Keywords: by Michael Beer & Russell A. Eisenstat
- 09 Feb 2018
- Working Paper Summaries
Developing Novel Drugs
- 24 Jul 2014
- Op-Ed
Reform Tax Law to Keep US Firms at Home
Editor's Note. Given a veritable flood over the last year of corporate "inversions"—US companies that reincoporate in other countries to take advantage of favorable tax rates and business regulations—lawmakers in Washington D.C. are debating how to respond.... View Details
- April 1984
- Supplement
Johnson & Johnson (A): Philosophy & Culture, James Burke, Video
By: Francis Aguilar
James Burke, chairman and CEO of Johnson & Johnson, discusses the company's philosophy and culture, with particular emphasis on the significance of the Credo. View Details
Keywords: Organizational Culture; Values and Beliefs; Mission and Purpose; Management Teams; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
Aguilar, Francis. "Johnson & Johnson (A): Philosophy & Culture, James Burke, Video." Harvard Business School Video Supplement 884-525, April 1984.
- September 2003 (Revised February 2007)
- Case
PolyMedica Corporation (A)
By: David F. Hawkins and Jacob Cohen
The Securities and Exchange Commission and investors question PolyMedica Corp.'s practice of capitalizing rather than expensing of direct-response advertising. View Details
Keywords: Activity Based Costing and Management; Business Earnings; Advertising; Private Sector; Budgets and Budgeting; Cost Management; Capital Markets; Marketing; Private Equity; Pharmaceutical Industry; Pharmaceutical Industry
Hawkins, David F., and Jacob Cohen. "PolyMedica Corporation (A)." Harvard Business School Case 104-023, September 2003. (Revised February 2007.)
- 12 Feb 2019
- First Look
New Research and Ideas, February 12, 2019
its 150th anniversary? Purchase this case:https://cb.hbsp.harvard.edu/cbmp/product/319046-PDF-ENG Harvard Business School Case 318-005 Dr. William Carson—Intrapreneurial Innovation in the Pharmaceutical Industry Dr. William Carson, an... View Details
Keywords: Dina Gerdeman
- 05 Jan 2011
- Op-Ed
Funding Unpredictability Around Stem-Cell Research Inflicts Heavy Cost on Scientific Progress
In light of the latest developments of the on-again, off-again, on-again government funding of human embryonic stem-cell research, it is time to consider the devastating implications of this chaotic funding environment. And to do that, one needs to understand how a... View Details
- 01 Jun 2009
- Lessons from the Classroom
The Challenges of Investing in Science-Based Innovation
In economic downtimes, businesses are apt to cut R&D projects that don't promise a speedy return on investment. But take a cue from smart science-based businesses, which view the recession as an opportunity to stoke up research and innovation for long-term... View Details
- 22 Apr 2008
- First Look
First Look: April 22, 2008
Business Harvard Business School Case 608-136 Novartis is a science-based drug company, which has important implications for its business strategy. It is one of the largest pharmaceutical companies in the world with over $38B in sales in... View Details
Keywords: Martha Lagace